[CONTACT]

[ABOUT]

[POLICY]

Denial of Natural Immunity in

Found at: gopher.erb.pw:70/roman/phlog2022/166.txt

Denial of Natural Immunity in Vaccine Mandates Unprecedented

COVID-19 injection mandates raise glaring questions, with a key
one revolving around natural immunity. Your immune system is
designed to work in response to exposure to an infectious agent
(https://bit.ly/3oMdIsB). Your adaptive immune system, specifically,
generates antibodies that are used to fight pathogens that your body
has previously encountered.
The U.S. Supreme Court recently (https://cnb.cx/3JIam1Z) upheld
a vaccine mandate (https://reut.rs/3uOMJjO) at the Centers for
Medicare & Medicaid Service (CMS), which is part of the U.S.
Department of Health and Human Services. The mandate affects
10.4 million health care workers employed at 76,000 medical
facilities, making no exceptions for those who have natural immunity
to COVID-19 due to prior infection (https://bit.ly/3rKXJwP).
The Labor Department’s Occupational Safety and Health Administration
(OSHA) was supposed to be in charge of enforcing the rule, which
would have affected more than 80 million U.S. workers. Of their
decision, the court noted:
"Although Congress has indisputably given OSHA the power to regulate
occupational dangers, it has not given that agency the power to regulate
public health more broadly. Requiring the vaccination of 84 million
Americans, selected simply because they work for employers with more
than 100 employees, certainly falls in the latter category."
Data from New York and California health officials, published in the
CDC’s (https://bit.ly/3JuwfkT) Morbidity and Mortality Weekly Report,
show that people who had previously had COVID-19 were far better
protected against COVID-19 infection with the Delta variant than
people who had been jabbed (https://bit.ly/3GNzkuI).
The report states:
“By the week beginning October 3, compared with COVID-19 cases
rates (https://bit.ly/3sHjug6) among unvaccinated persons without a
previous COVID-19 diagnosis, case rates among vaccinated persons
without a previous COVID-19 diagnosis were 6.2-fold (California)
and 4.5-fold (New York) lower; rates were substantially lower among
both groups with previous COVID-19 diagnoses, including 29.0-fold
(California) and 14.7-fold lower (New York) among unvaccinated
persons with a previous diagnosis, and 32.5-fold (California) and
19.8-fold lower (New York) among vaccinated persons with a previous
diagnosis of COVID-19.
In another study, researchers reviewed studies published in PubMed
and found that the risk of reinfection (https://bit.ly/3GQbzCl) with
SARS-CoV-2 decreased by 80.5% to 100% among people who had
previously had COVID-19. Additional research cited in their review
found:
- Among 9,119 people who had previously had COVID-19, only 0.7%
became reinfected.
- At the Cleveland Clinic in Cleveland, Ohio, the incidence rate of
COVID-19 among those who had not previously been infected was
4.3 per 100 people; the COVID-19 incidence rate among those who
had previously been infected was zero per 100 people.
- The frequency of hospitalization due to a repeated COVID-19
infection was five per14,840 people, or .03%, according to an
Austrian study; the frequency of death due to a repeated infection
was one per 14,840 people, or .01%.
In a letter to the editor of The New England Journal of Medicine,
Dr. Roberto Bertollini of the Ministry of Public Health in Doha,
Qatar, and colleagues estimated the efficacy of natural immunity
against reinfection by comparing data in the national cohort
(https://bit.ly/36e2ira).
They found that immunity acquired from previous infection was
92.3% effective against reinfection with the beta variant and 97.6%
effective against reinfection with the alpha variant. Protection
persisted even one year after the primary infection.
Researchers from Ireland also conducted a systematic review
including 615,777 people who had recovered from COVID-19, with
a maximum duration of follow-up of more than 10 months.
“Reinfection was an uncommon event,” they noted, “… with no
study reporting an increase in the risk of reinfection over time.”
The absolute reinfection rate ranged from zero percent to 1.1%,
while the median reinfection rate was just 0.27%.
(https://bit.ly/3Jsmxji)
Another study revealed similarly reassuring results. It followed
43,044 SARS-CoV-2 antibody-positive people for up to 35 weeks,
and only 0.7% were reinfected. When genome sequencing was
applied to estimate population-level risk of reinfection, the risk
was estimated at 0.1%.
Again, there was no indication of waning immunity over seven
months of follow-up, with the researchers concluding, “Reinfection
is rare. Natural infection appears to elicit strong protection against
reinfection with an efficacy >90% for at least seven months.”
Another study from Israel (https://bit.ly/3GRFs58) also had
researchers questioning “the need to vaccinate previously-infected
individuals,” after their analysis showed similar risks of reinfection
among those with vaccine-induced or natural immunity. Specifically,
vaccination had an overall estimated efficacy of preventing
reinfection of 92.8%, compared to 94.8% for natural immunity
acquired via prior infection (https://bit.ly/3BmsN97).
Evidence from Washington University School of Medicine also
shows long-lasting immunity to COVID-19
(https://go.nature.com/3LqGhFA) exists in those who’ve recovered
from the natural infection. At both seven months and 11 months after
infection, most of the participants had bone marrow plasma cells
(BMPCs) that secreted antibodies specific for the spike protein
encoded by SARS-CoV-2 (https://go.nature.com/3Jqf1p4).
The BMPCs were found in amounts similar to those found in people
who had been vaccinated against tetanus or diphtheria, which are
considered to provide long-lasting immunity. “Overall, our data
provide strong evidence that SARS-CoV-2 infection in humans robustly
establishes the two arms of humoral immune memory: long-lived
BMPCs and memory B cells,” the researchers noted.
If you’ve had COVID-19, getting injected may pose an even greater
risk, to the extent that Dr. Hooman Noorchashm, Ph.D., a cardiac
surgeon and patient advocate, has repeatedly warned the FDA that
“clear and present danger” exists for those who have had COVID-19
and subsequently get the injection.
At issue are viral antigens that remain in your body after you are
naturally infected. The immune response reactivated by the COVID-19
injection can trigger inflammation in tissues where the viral antigens
are present. The inner lining of blood vessels, the lungs and the brain
may be particularly at risk of such inflammation and damage.25
Writing in Lancet Infectious Diseases (https://bit.ly/3oPZ7wb),
researchers also explained:
“Some people who have recovered from COVID-19 might not benefit
from COVID-19 vaccination. In fact, one study found that previous
COVID-19 was associated with increased adverse events following
vaccination with the Comirnaty BNT162b2 mRNA vaccine
(Pfizer–BioNTech). In addition, there are rare reports of serious
adverse events following COVID-19 vaccination.”
As it stands, the U.S. CDC continues to push universal injections,
despite past infection status, and natural immunity is not considered
adequate to enter the growing number of venues requiring vaccine
passports. This isn’t the case in Switzerland, where residents who
have had COVID-19 in the past 12 months are considered to be
equally as protected as those who’ve been injected
(https://bit.ly/3BiP47X).
The end-goal of vaccine passports, though, isn’t to simply track one
shot. Your entire identity, including your medical history, finances,
sexual orientation and much more, could soon be stored in a mobile
app that’s increasingly required to partake in society. While some
might call this convenience, others would call it oppression.
You can fight back against vaccine mandates (https://bit.ly/34D4Yhq)
and their related vaccine passports by not supporting establishments
that require proof of a shot or a negative test, and avoiding all
digital identities and vaccine ID passports offered as a means of
increasing “access” or “convenience.”


AD: